Pfizer and Biontech, 90% Effective Vaccine for Covid-19
"Pfizer" and "Biontech" have announced that the vaccine they are developing for Covid-19 is "90% effective", after preliminary analysis of results from the third phase of clinical trials, the last before submitting the license application.
The two companies said in a joint statement that “this vaccine’s effectiveness” was measured by comparing the number of participants infected with the emerging coronavirus in the group that received the vaccine and the number of infected people in another group who received a placebo vaccine, seven days after receiving the second dose and 28 days after receiving the first dose. As reported by “Agence France-Presse.”
The vaccine produces nucleic acids that stimulate cells in the human body to produce virus-like proteins, and these proteins stimulate the human body’s immune response against the Corona virus.
Pfizer has entered into an agreement to sell 100 million doses of its vaccine to the United States government, giving it the option to purchase an additional 500 million doses.
The company does many similar deals with other governments, including the European Union.
The test protocol issued an order to speed up the analysis of the results of this vaccine, but scientists, biologists and clinical testing experts have warned of the risks of granting urgent approval, preferring to test the vaccine for a few more months, to ensure its effectiveness and possible side effects.